2020 实践建议：COVID-19患者糖尿病的管理

2020-04-23 国外内分泌相关专家小组（统称） Lancet Diabetes Endocrinol. 2020 Apr 23

糖尿病是COVID-19患者最重要的共病之一，糖尿病患者发生严重并发症的风险增加，包括成人呼吸窘迫综合征和多器官衰竭。本文是由国际内分泌领域专家小组针对COVID-19流行期间糖尿病的管理提供指导建议

中文标题：

英文标题：

Practical recommendations for the management of diabetes in patients with COVID-19.

发布机构：

国外内分泌相关专家小组（统称）

发布日期：

2020-04-23

简要介绍：

糖尿病是COVID-19患者最重要的共病之一，糖尿病患者发生严重并发症的风险增加，包括成人呼吸窘迫综合征和多器官衰竭。本文是由国际内分泌领域专家小组针对COVID-19流行期间糖尿病的管理提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=c4b261c001901054, title=2020 实践建议：COVID-19患者糖尿病的管理, enTitle=Practical recommendations for the management of diabetes in patients with COVID-19., guiderFrom=Lancet Diabetes Endocrinol. 2020 Apr 23, authorId=0, author=, summary=糖尿病是COVID-19患者最重要的共病之一，糖尿病患者发生严重并发症的风险增加，包括成人呼吸窘迫综合征和多器官衰竭。本文是由国际内分泌领域专家小组针对COVID-19流行期间糖尿病的管理提供指导建议, cover=https://img.medsci.cn/202058/1588951478604_2020535.jpg, journalId=0, articlesId=null, associationId=949, associationName=国外内分泌相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Apr 23 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>糖尿病是COVID-19患者最重要的共病之一，糖尿病患者发生严重并发症的风险增加，包括成人呼吸窘迫综合征和多器官衰竭。本文是由国际内分泌领域专家小组针对COVID-19流行期间糖尿病的管理提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=216, tagName=糖尿病), TagDto(tagId=102190, tagName= COVID-19)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=216, guiderKeyword=糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1873, appHits=106, showAppHits=61, pcHits=483, showPcHits=1831, likes=1, shares=7, comments=8, approvalStatus=1, publishedTime=Fri May 08 23:57:40 CST 2020, publishedTimeString=2020-04-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri May 08 23:24:41 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 16:43:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 实践建议：COVID-19患者糖尿病的管理.pdf)])

2020 实践建议：COVID-19患者糖尿病的管理.pdf

下载请点击：

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=949721, encodeId=9eb5949e211c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82c35471352, createdName=kqch1881, createdTime=Sat Mar 20 15:27:55 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920412, encodeId=457a920412bf, content=这个正需要分享给好友的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Wed Jan 27 20:26:31 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892804, encodeId=c3ba892804f0, content=及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809798, encodeId=4aa4809e98a6, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:45:54 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808792, encodeId=42f8808e92f9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:41 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
2021-03-20 kqch1881

好

70 0
[GetPortalCommentsPageByObjectIdResponse(id=949721, encodeId=9eb5949e211c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82c35471352, createdName=kqch1881, createdTime=Sat Mar 20 15:27:55 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920412, encodeId=457a920412bf, content=这个正需要分享给好友的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Wed Jan 27 20:26:31 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892804, encodeId=c3ba892804f0, content=及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809798, encodeId=4aa4809e98a6, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:45:54 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808792, encodeId=42f8808e92f9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:41 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
2021-01-27 1257c336m18暂无昵称

这个正需要分享给好友的

72 0
[GetPortalCommentsPageByObjectIdResponse(id=949721, encodeId=9eb5949e211c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82c35471352, createdName=kqch1881, createdTime=Sat Mar 20 15:27:55 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920412, encodeId=457a920412bf, content=这个正需要分享给好友的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Wed Jan 27 20:26:31 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892804, encodeId=c3ba892804f0, content=及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809798, encodeId=4aa4809e98a6, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:45:54 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808792, encodeId=42f8808e92f9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:41 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
2020-10-18 星痕

及时

84 0
[GetPortalCommentsPageByObjectIdResponse(id=949721, encodeId=9eb5949e211c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82c35471352, createdName=kqch1881, createdTime=Sat Mar 20 15:27:55 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920412, encodeId=457a920412bf, content=这个正需要分享给好友的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Wed Jan 27 20:26:31 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892804, encodeId=c3ba892804f0, content=及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809798, encodeId=4aa4809e98a6, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:45:54 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808792, encodeId=42f8808e92f9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:41 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
2020-08-17 ms5000002046462755

好

95 0
[GetPortalCommentsPageByObjectIdResponse(id=949721, encodeId=9eb5949e211c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82c35471352, createdName=kqch1881, createdTime=Sat Mar 20 15:27:55 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920412, encodeId=457a920412bf, content=这个正需要分享给好友的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Wed Jan 27 20:26:31 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892804, encodeId=c3ba892804f0, content=及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809798, encodeId=4aa4809e98a6, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:45:54 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808792, encodeId=42f8808e92f9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:41 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
2020-08-14 ms5000002046462755

好

88 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科指南

2020 实践建议：COVID-19患者糖尿病的管理

相关指南

拓展阅读

科室

工具

服务